News & Articles

The Collaboration is poised to deliver a range of ready-to-use bioprocess impurity reagent sets

Top talks and new resources detailing key developments in the fields of clinical research and diagnostics are now available on demand

Univercells Technologies will work with VectorBuilder to develop and optimize NevoLine Upstream platform and scale-X bioreactors for the production of custom viral vectors

The new media panel, gene kit and advanced resins help reduce manufacturing costs while increasing the viability of gene therapies

Watch exclusive interviews with leading industry experts on the importance of precision cold storage equipment

Watch this on-demand webinar to learn how an advanced spatial analysis workflow can be used to analyze the infiltration of CD8 positive cells across the tumor-stroma interface

The ultra-sensitive biomarker platform evaluates plasma neurofilament light’s utility across 13 neurodegenerative disorders, Down syndrome and depression

Catch up on this on-demand webinar to discover how combining multiplexing with HTS could streamline your drug discovery

The new XIENCE Skypoint stent received FDA approval in the U.S. and CE Mark approval in Europe

The self-collection kits facilitate raw saliva collection to aid global SARS-CoV-2 research and surveillance efforts

In this guest editorial, Michaël van der Jagt, CEO of Parx Materials, discusses how the human immune system can inspire innovation

The clinical data for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity

A research team led by physicians of the Karl Landsteiner University of Health Sciences in Krems uncovers a pivotal role for a regulator protein in tumor bone marrow angiogenesis

Collaboration aims to provide new workflows, faster acquisition speeds and deeper resolution

Panbio COVID-19 Antigen Self-Test is approved for sale directly to consumers, enabling fast, convenient coronavirus testing

The Panbio self-test features a minimally invasive nasal swab and delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology

The facility will be capable of manufacturing batches ranging from those for early-stage research to GMP for clinical and future commercial uses